AA
BHVN

ALPS Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

ALPS Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-35,206
Closed -$1.32M – 913
2017
Q3 		$1.32M Buy
35,206
+4,309
+14% +$131K 0.01% 218
2017
Q2 		$772K Buy
+30,897
New +$712K 0.01% 276

Other funds holding BHVN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ALPS Advisors's BHVN Position: Q4 2017 in Review

ALPS Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2017, closing a stake of 35,206 shares — an estimated $1.32M sold.

ALPS Advisors first reported a position in BHVN in Q2 2017 and held it in 2 quarters. The position peaked at $1.32M in Q3 2017. 90 funds tracked by Wall St. Rank hold BHVN as of Q4 2017.

  • ALPS Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2017 after selling out during the quarter.
  • ALPS Advisors sold 35,206 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2017, an estimated $1.32M.
  • ALPS Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 2 quarters.
  • ALPS Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.32M in Q3 2017.
  • 90 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.